Edition:
United States

Addex Therapeutics Ltd (ADXN.S)

ADXN.S on Swiss Exchange

1.68CHF
24 May 2019
Change (% chg)

CHF0.03 (+1.82%)
Prev Close
CHF1.65
Open
CHF1.65
Day's High
CHF1.68
Day's Low
CHF1.63
Volume
3,580
Avg. Vol
28,215
52-wk High
CHF3.05
52-wk Low
CHF1.59

About

Addex Therapeutics Ltd is a Switzerland-based company, that discovers and develops a class of small molecule drugs, allosteric modulators. Its two products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or is being developed by the Company to treat Parkinson’... (more)
No analyst recommendations are available for .

Overall

Beta: -0.90
Market Cap(Mil.): CHF33.69
Shares Outstanding(Mil.): 15.38
Dividend: --
Yield (%): --

Financials

  ADXN.S Industry Sector
P/E (TTM): -- 69.30 32.55
EPS (TTM): -0.32 -- --
ROI: -165.48 8.91 13.82
ROE: -193.92 10.05 15.25

BRIEF-Addex Therapeutics Increases Issued Share Capital

* HAS INCREASED ITS CAPITAL FROM 28,564,031 TO 32,848,635 THROUGH THE ISSUE OF 4,284,604 NEW REGISTERED SHARES

May 20 2019

BRIEF-Addex Therapeutics FY Net Loss At CHF 1.6 Mln

* NET LOSS FOR 2018 WAS CHF1.6 MILLION COMPARED TO CHF3.2 MILLION FOR 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 30 2019

CORRECTED-BRIEF-Addex Therapeutics FY Oper Income Up At CHF 6.8 Mln

* FY NET CASH FROM OPERATING ACTIVITIES OF CHF1.9 MILLION (2017: CHF1.2 MILLION)

Mar 08 2019

BRIEF-Addex And Indivior To Accelerate Additional GABAB PAM Compounds For Addiction

* ADDEX AND INDIVIOR TO ACCELERATE ADDITIONAL GABAB PAM COMPOUNDS FOR ADDICTION AS INDIVIOR ELECTS TO STOP DEVELOPMENT OF ADX71441 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 14 2019

Earnings vs. Estimates